EMA Authorised: Azilect (rasagiline) — Teva B.V.

View source ↗

Summary

The EMA authorized Azilect (rasagiline) for Parkinson disease with Teva B.V. as the marketing authorization holder. Decision date: 07/04/2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Azilect (rasagiline)

Snippet

Status: Authorised. Therapeutic area: Parkinson Disease. MAH: Teva B.V.. Decision date: 07/04/2025